Therapeutic effects of L/N type calcium channel blocker cilnidipine and L type calcium channel blockers on hypertensive patients with chronic kidney disease
Phase 4
- Conditions
- Hypertension, Chronic kidney disease
- Registration Number
- JPRN-UMIN000001593
- Lead Sponsor
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients already treated with cilnidipine, 2. History of hypersensitivity to cilnidipine, 3. Severe hypertension (clinic BP more than 180/100 mmHg), 4. Severe liver disorder, or severe biliary atresia, 5. Pregnant women, or women suspected of being pregnant.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Clinic blood pressure. 2. Ambulatory blood pressure monitoring. 3. Renal function: eGFR, urinary protein/albuminon excretion. 4. Renin-angiotensin system, inflammatory and oxidative stress markers, PRA, urinary angiotensinogen, plasma cathecholamine. 5. Cardiac function: BNP, UCG. 6. Vascular function: ABI/baPWV.
- Secondary Outcome Measures
Name Time Method